Do ACE Inhibitors early in pregnancy increase risk of birth defects?
This study by Bateman et al. (Obstetrics and Gynecology, 2017) aimed to determine if exposure to angiotensin-converting enzyme (ACE) inhibitors during the first trimester is associated with risk of congenital, cardiac, and central nervous system malformations.
Observational Cohort study
The study examined 1,333,624 pregnancies, 4,107 of which were exposed to ACE inhibitors in the first trimester. When the study was restricted to pregnancies complicated with chronic hypertension and after accounting for other confounding factors, there was no increased risk found for congenital malformations between women exposed to ACE inhibitors and those not exposed. A major strength of this study is the cohort size, which is one of the largest ever developed for the study of drugs in pregnancy.
Please login to access ObGFirst and the T2 US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan